Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Douglas T Gjerde currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to a distinct examiner, which indicates a very focused interaction with the USPTO at this time. Because the entire active portfolio consists of a single case, the prosecution strategy is highly concentrated. This suggests that the current legal efforts are directed toward a specific technical advancement within the pharmaceutical field, requiring a precise approach to patenting. The involvement of a distinct art unit means the portfolio is subject to the unique examination style of a specific group.
CHESTNUT, BARRY A is the busiest examiner for this portfolio, responsible for 1 busiest examiner pending action. Since there is only a single examiner and a single art unit involved, the outcome of the prosecution depends on the review standards of that specific department. Practitioners should note that the lack of diversification across different art units means the portfolio cannot compare rejection patterns across multiple examiners. The 1 pending office action represents the full extent of the active Biotechnology & Pharmaceuticals workload, and the centralized nature of this review may allow for a more direct dialogue with the USPTO. Maintaining consistency in technical arguments is crucial when a portfolio is confined to a single point of contact.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHESTNUT, BARRY A | 1 | 73.9% | +6.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18683880 | UNDIRECTED MUTATED MRNA VACCINE | CHESTNUT, BARRY A | — |
| Art Unit | Apps |
|---|---|
| 1672 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18683880 | UNDIRECTED MUTATED MRNA VACCINE | CHESTNUT, BARRY A | 1672 | §102§103 | Non-Final OA | — | Pending | Feb 15, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDouglas T Gjerde has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Barry A Chestnut has the most, with 1 of Douglas T Gjerde's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
